These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29495245)

  • 21. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders.
    Shah U; Kowalski TJ
    Vitam Horm; 2010; 84():415-48. PubMed ID: 21094910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
    Moritoh Y; Takeuchi K; Hazama M
    J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes.
    Yoshida S; Tanaka H; Oshima H; Yamazaki T; Yonetoku Y; Ohishi T; Matsui T; Shibasaki M
    Biochem Biophys Res Commun; 2010 Oct; 400(4):745-51. PubMed ID: 20816753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion.
    Yoshida S; Ohishi T; Matsui T; Shibasaki M
    Biochem Biophys Res Commun; 2010 Sep; 400(3):437-41. PubMed ID: 20804735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oleoyl-lysophosphatidylinositol enhances glucagon-like peptide-1 secretion from enteroendocrine L-cells through GPR119.
    Arifin SA; Paternoster S; Carlessi R; Casari I; Ekberg JH; Maffucci T; Newsholme P; Rosenkilde MM; Falasca M
    Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Sep; 1863(9):1132-1141. PubMed ID: 29883799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. APD668, a G protein-coupled receptor 119 agonist improves fat tolerance and attenuates fatty liver in high-trans fat diet induced steatohepatitis model in C57BL/6 mice.
    Bahirat UA; Shenoy RR; Goel RN; Nemmani KV
    Eur J Pharmacol; 2017 Apr; 801():35-45. PubMed ID: 28274625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
    Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
    Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.
    Green BD; Gault VA; Mooney MH; Irwin N; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    J Mol Endocrinol; 2003 Dec; 31(3):529-40. PubMed ID: 14664713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral 2-oleyl glyceryl ether improves glucose tolerance in mice through the GPR119 receptor.
    Hassing HA; Engelstoft MS; Sichlau RM; Madsen AN; Rehfeld JF; Pedersen J; Jones RM; Holst JJ; Schwartz TW; Rosenkilde MM; Hansen HS
    Biofactors; 2016 Nov; 42(6):665-673. PubMed ID: 27297962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
    Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Sakagami H; Kitsunai H; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
    Mol Metab; 2017 Feb; 6(2):226-231. PubMed ID: 28180064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.
    Sangle GV; Lauffer LM; Grieco A; Trivedi S; Iakoubov R; Brubaker PL
    Endocrinology; 2012 Feb; 153(2):564-73. PubMed ID: 22186413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
    Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition.
    Chang E; Kim L; Choi JM; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Park DI; Park CY
    Metabolism; 2015 May; 64(5):633-41. PubMed ID: 25704082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HD047703, a New Promising Anti-Diabetic Drug Candidate: In Vivo Preclinical Studies.
    Kim S; Kim DH; Kim YS; Ha TY; Yang J; Park SH; Jeong KW; Rhee JK
    Biomol Ther (Seoul); 2014 Sep; 22(5):400-5. PubMed ID: 25414769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contribution of intestinal dipeptidyl peptidase-4 inhibition for incretin-dependent improved glucose tolerance in mice.
    Yamashita S; Kawakami Y; Sato H; Sugitani S; Goto M; Kato N
    Eur J Pharmacol; 2019 Sep; 859():172521. PubMed ID: 31276666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice.
    McKillop AM; Moran BM; Abdel-Wahab YH; Gormley NM; Flatt PR
    Diabetologia; 2016 Dec; 59(12):2674-2685. PubMed ID: 27677765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.
    Moritoh Y; Takeuchi K; Asakawa T; Kataoka O; Odaka H
    Eur J Pharmacol; 2008 Jul; 588(2-3):325-32. PubMed ID: 18499100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.
    Green BD; Mooney MH; Gault VA; Irwin N; Bailey CJ; Harriott P; Greer B; O'Harte FP; Flatt PR
    J Endocrinol; 2004 Mar; 180(3):379-88. PubMed ID: 15012592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological stimulation of serotonin 5-HT1B receptors enhances increases in plasma active glucagon-like peptide-1 levels induced by dipeptidyl peptidase-4 inhibition independently of feeding in mice.
    Nonogaki K; Kaji T
    Diabetes Metab; 2015 Nov; 41(5):425-8. PubMed ID: 26234524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. beta-cell failure in diabetes and preservation by clinical treatment.
    Wajchenberg BL
    Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.